3-hydroxykynurenine has been researched along with Psychotic Disorders in 5 studies
3-hydroxykynurenine: RN given refers to cpd without isomeric designation
3-hydroxykynurenine : A hydroxykynurenine that is kynurenine substituted by a hydroxy group at position 3.
hydroxykynurenine : A hydroxy-amino acid that is kynurenine substituted by a single hydroxy group at unspecified position. A "closed" class.
Psychotic Disorders: Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Depression is hypothesized to be causally associated with an imbalance in the kynurenine pathway, with an increased metabolism down the 3-hydroxykynurenine (3HK) branch of the pathway leading to increased levels of the neurotoxic metabolite, quinolinic acid (QA), which is a putative N-methyl-d-aspartate (NMDA) receptor agonist." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| "A subgroup of individuals with mood and psychotic disorders shows evidence of inflammation that leads to activation of the kynurenine pathway and the increased production of neuroactive kynurenine metabolites." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| " In contrast, schizophrenia and psychosis are hypothesized to arise from increased metabolism of the NMDA receptor antagonist, kynurenic acid (KynA), leading to hypofunction of GABAergic interneurons, the disinhibition of pyramidal neurons and striatal hyperdopaminergia." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| "Depression is hypothesized to be causally associated with an imbalance in the kynurenine pathway, with an increased metabolism down the 3-hydroxykynurenine (3HK) branch of the pathway leading to increased levels of the neurotoxic metabolite, quinolinic acid (QA), which is a putative N-methyl-d-aspartate (NMDA) receptor agonist." | 1.46 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| "Kynurenine was significantly lower in patients with PP and PD as compared to healthy postpartum women (p=0." | 1.43 | Tryptophan pathway alterations in the postpartum period and in acute postpartum psychosis and depression. ( Bergink, V; Burgerhout, KM; Drexhage, HA; Hoogendijk, WJ; Kushner, SA; Myint, AM; Schütze, G; Schwarz, MJ; Veen, C, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wurfel, BE | 1 |
| Drevets, WC | 1 |
| Bliss, SA | 1 |
| McMillin, JR | 1 |
| Suzuki, H | 1 |
| Ford, BN | 1 |
| Morris, HM | 1 |
| Teague, TK | 1 |
| Dantzer, R | 1 |
| Savitz, JB | 1 |
| Curto, M | 1 |
| Lionetto, L | 1 |
| Fazio, F | 1 |
| Corigliano, V | 1 |
| Comparelli, A | 1 |
| Ferracuti, S | 1 |
| Simmaco, M | 1 |
| Nicoletti, F | 1 |
| Baldessarini, RJ | 1 |
| Shilov, IuE | 1 |
| Bezrukov, MV | 1 |
| Veen, C | 1 |
| Myint, AM | 1 |
| Burgerhout, KM | 1 |
| Schwarz, MJ | 1 |
| Schütze, G | 1 |
| Kushner, SA | 1 |
| Hoogendijk, WJ | 1 |
| Drexhage, HA | 1 |
| Bergink, V | 1 |
| Condray, R | 1 |
| Dougherty, GG | 1 |
| Keshavan, MS | 1 |
| Reddy, RD | 1 |
| Haas, GL | 1 |
| Montrose, DM | 1 |
| Matson, WR | 1 |
| McEvoy, J | 1 |
| Kaddurah-Daouk, R | 1 |
| Yao, JK | 1 |
1 review available for 3-hydroxykynurenine and Psychotic Disorders
| Article | Year |
|---|---|
[Kynurenines in pathogenesis of endogenous psychiatric disorders].
Topics: Humans; Hydroxyindoleacetic Acid; Kynurenine; Mental Disorders; Psychotic Disorders; Tryptophan; Xan | 2013 |
1 trial available for 3-hydroxykynurenine and Psychotic Disorders
| Article | Year |
|---|---|
3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chromatography, High Pressu | 2011 |
3 other studies available for 3-hydroxykynurenine and Psychotic Disorders
| Article | Year |
|---|---|
Serum kynurenic acid is reduced in affective psychosis.
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Corpus Striatum; Cytokines; Depression; Dep | 2017 |
Serum xanthurenic acid levels: Reduced in subjects at ultra high risk for psychosis.
Topics: Adolescent; Adult; Disease Progression; Female; Humans; Hydroxyindoleacetic Acid; Kynurenic Acid; Ky | 2019 |
Tryptophan pathway alterations in the postpartum period and in acute postpartum psychosis and depression.
Topics: Adult; Depression, Postpartum; Female; Humans; Hydroxyindoleacetic Acid; Kynurenic Acid; Kynurenine; | 2016 |